{"ticker": {"uuid": "ee567459-23e0-406b-9d4b-6ad8ff4cbad0", "symbol": "IMTX", "name": "Immatics NV", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "(IMTX) and the Role of Price-Sensitive Allocations", "summary": "Immatics N.v. (NASDAQ: IMTX) is showing weak near-term sentiment but strong mid and long-term outlooks, with breakdown currently underway. AI models provide distinct trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe sig", "url": "https://news.stocktradersdaily.com/news_release/1/IMTX_and_the_Role_of_Price-Sensitive_Allocations_071426052802_1784021282.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T05:28:00", "published_display": "14 Jul 2026 05:28", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immatics stock holds attention. The focus shifts to its pipeline.", "summary": "Immatics N.V. (IMTX) is a cancer immunotherapy company with a pipeline focused on T-cell receptor (TCR) based therapies and cell therapy programs, listed on Nasdaq. The company's value is closely tied to its clinical pipeline performance, including trial milestones, safety signal", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immatics-stock-holds-attention-the-focus-shifts-to-its-pipeline/69716286", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:21:00", "published_display": "07 Jul 2026 17:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the IMTX Inflection", "summary": "This article analyzes Immatics N.v. (NASDAQ: IMTX), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 59.0:1 risk-reward setup targeting an 18.3% gain against 0.3% risk. The piece provides institutional trading strategies for", "url": "https://news.stocktradersdaily.com/news_release/1/Responsive_Playbooks_and_the_IMTX_Inflection_070326042002_1783066802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-04T03:10:06", "published_display": "04 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. Actuals & Estimates (NASDAQ:IMTX)", "summary": "This article provides detailed financial actuals and analyst estimates for Immatics N.V. (IMTX), including stock price performance, growth trends, future forecasts, and historical highs and lows. It covers income statement, balance sheet, cash flow, and valuation metrics, along w", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-29T13:14:47", "published_display": "29 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immatics N.V. \u2013 NASDAQ:IMTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPNXB4bk13R0ttODNCY29YRWh2SGtjSUdmcml1SlRfb1ZfOHRoT2hQRHM5cU12c293dm1WOFpqWTM3em9CZ1prMThCRHlzX3FkdlZ3S1hLUHZJOFhJQnZUTzhQVzBhc0FwZUl3djBjVEt5bmpxYnRQQUZjYndKdTdWenI3bGwtU3hlRGVycmJWTVE0TFJObUNDTkFTV3I?oc=5", "source_name": "TradingView", "published_at": "2026-06-28T20:54:51+00:00", "published_display": "28 Jun 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immatics N.V. \u2013 NASDAQ:IMTX", "summary": "This article provides a brief financial overview of Immatics N.V., focusing on its forward price-to-sales ratio. It indicates the stock's performance on the Nasdaq Stock Market under the ticker IMTX and states that the market is currently closed with no trades. The content primar", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:32", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Immatics N.V. \u2013 MUN:4A3", "summary": "This article focuses on the enterprise value to EBIT forward for Immatics N.V., traded on the Munich Stock Exchange under the ticker 4A3. It appears to be a financial data presentation and analysis page from TradingView, providing an overview of the company's financial metrics. T", "url": "https://www.tradingview.com/symbols/MUN-4A3/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:40", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immatics N.V. \u2013 NASDAQ:IMTX", "summary": "The article provides a financial overview of Immatics N.V. (NASDAQ: IMTX), focusing on its price-to-earnings forward metric. It highlights that the market was closed with no trades recorded at the time of the data. The content primarily serves as a placeholder or financial data p", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:23", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Immatics N.V. (IMTX) stock, including analyst ratings, historical performance, and financial data. It covers frequently asked questions regarding the stock's current price, volatility, market capitalization, earnings,", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T07:11:10", "published_display": "27 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. Actuals & Estimates (FWB:4A3)", "summary": "This article provides key financial actuals and estimates for Immatics N.V. (FWB:4A3), including analyst price targets, historical stock performance, and upcoming earnings dates. It also details the company's past quarterly earnings, revenue, net income, EBITDA, and employee coun", "url": "https://www.tradingview.com/symbols/FWB-4A3/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:53", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award", "summary": "Immatics N.V. (IMTX) director Adam Leo Stone was granted 48,000 stock options, with an exercise price of $9.09 per share and an expiration date of June 15, 2036. These options will vest 100% on June 16, 2026, marking them as a compensation-related award rather than an open-market", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-578f11fe8580.html", "source_name": "Stock Titan", "published_at": "2026-06-22T00:40:32", "published_display": "22 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) awards director Alise Reicin 48,000 stock options", "summary": "Immatics N.V. (IMTX) director Alise Reicin was granted 48,000 stock options as compensation. These options allow her to purchase Immatics ordinary shares at an exercise price of $9.09 per share, expire on June 15, 2036, and will vest 100% on June 16, 2026. This transaction was re", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-1a4c67d05561.html", "source_name": "Stock Titan", "published_at": "2026-06-22T00:40:32", "published_display": "22 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Shareholders Approve All Proposals at June 18, 2026 AGM", "summary": "Immatics N.V. held its Annual General Meeting on June 18, 2026, where shareholders approved all resolutions, including the adoption of annual accounts, re-election of directors, extension of share repurchase authority, and approval of a 2026 stock option plan. Despite strong shar", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMTX/pressreleases/2561647/immatics-shareholders-approve-all-proposals-at-june-18-2026-agm/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T09:40:29", "published_display": "20 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director receives 48,000 stock options vesting in 2026", "summary": "Immatics N.V. (IMTX) director Carter Paul Rutherford was granted 48,000 stock options with an exercise price of $9.09 per share, set to expire on June 15, 2036. These options will vest entirely on June 16, 2026, which is the first anniversary of the grant date. This award is a fo", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-ec0814e4dbbf.html", "source_name": "Stock Titan", "published_at": "2026-06-19T23:39:18", "published_display": "19 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Immatics NV (IMTXW), focusing on support, resistance, and various indicators including MACD, RSI, KDJ, and moving averages. The analysis suggests a \"Sell\" signal based on both technical indicators and moving averages due to low volati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/technical", "source_name": "TradingKey", "published_at": "2026-06-19T22:41:11", "published_display": "19 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) director awarded 48,000 stock options at $9.09", "summary": "Immatics N.V. director Peter Alan Chambre was granted 48,000 stock options as part of his compensation, allowing him to purchase ordinary shares at an exercise price of $9.09 each. These options will vest 100% on June 16, 2026, and are set to expire on June 15, 2036. This transac", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-c4af1e59591b.html", "source_name": "Stock Titan", "published_at": "2026-06-19T09:10:41", "published_display": "19 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares", "summary": "Immatics N.V. (IMTX) director Eliot Forster has been granted stock options for 48,000 ordinary shares. These options have an exercise price of $9.09 per share and a full vesting date of June 16, 2026, one year from the grant date. The options are set to expire on June 15, 2036.", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-80ec640acc2d.html", "source_name": "Stock Titan", "published_at": "2026-06-19T08:41:11", "published_display": "19 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director receives grant of 48,000 stock options at $9.09", "summary": "Immatics N.V. director Michael G. Atieh was granted 48,000 stock options with an exercise price of $9.09 per share. These options will vest 100% on June 16, 2026, which is the first anniversary of the grant date, and are set to expire on June 15, 2036. This transaction is classif", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-25c881ea3108.html", "source_name": "Stock Titan", "published_at": "2026-06-19T08:41:11", "published_display": "19 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director Mathias Hothum awarded 48,000 options at $9.09 strike", "summary": "Immatics N.V. (IMTX) Director Mathias Hothum was granted 48,000 stock options at an exercise price of $9.09 per share. These compensation-related options vest 100% on June 16, 2026, and will expire on June 15, 2036. Following this transaction, Hothum holds 48,000 derivative secur", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-1d2ca4ee7272.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:27", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) 2026 AGM sees all voting items approved and strong turnout", "summary": "Immatics N.V. held its Annual General Meeting of Shareholders on June 18, 2026, where all agenda voting items were approved by the required majorities. The meeting had a strong turnout, with approximately 64.07% of the company's issued share capital represented. The minutes of th", "url": "https://www.stocktitan.net/sec-filings/IMTX/6-k-immatics-n-v-current-report-foreign-issuer-ae7c96666072.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:27", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Immatics NV (IMTXW), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it states that relevant data for these valuation metrics have not yet been disclosed by the company. The article serves primarily as a framewo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:12", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) Stock Looks Expensive After PRAME Platform Update And Cash Runway To 2028", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immatics NV's (IMTX) dividend and stock split history, noting that no dividends have been distributed in the past five years and no stock split data is available. It presents current stock performance data, including market capitalization and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:45", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article from TradingKey provides a financial health analysis for Immatics NV (IMTXW), focusing on profitability and its balance sheet. However, the report indicates that relevant financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholde", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:45", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article concerns the revenue breakdown for Immatics NV (IMTXW), detailing its business segments, regional revenue, and profit contribution. However, the critical financial data required for this breakdown has not yet been disclosed by the company, rendering the specific break", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T14:41:33", "published_display": "17 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Immatics NV (IMTX) has an earnings forecast score of 8.83, ranking 50th in the biotechnology industry. Analysts overwhelmingly recommend a \"Buy\" for IMTX, with a target price of $17.50, suggesting a potential upside of over 100%. The company expects significant revenue in the upc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T13:41:33", "published_display": "17 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNenRCSWJQTEw3cDB3ZUtBb3RLS3Nmb3Z0SEhmbTkzNHdhV1BYVWliUnhZWi1QNElhMkVBcU5xX25FUUZ6anR2TmRPdkpWN2lILWdHaHFtLUtuUHZGZGxRSFFUaDM4UHdFU09pLWJVRTJoaUpDeUpjNnFvb3o1bTdKRmlqYVVSSHZhY1ljdU9TSGNkcjdWaF9kOE9nUjNBOS16Yko4SnZpbw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting", "summary": "Immatics announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma, presented at the 2026 ASCO Annual Meeting. The one-time infusion therapy demonstrated significant anti-tumor activity in difficult-to-treat gynecologic ", "url": "https://markets.businessinsider.com/news/stocks/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting-1036209654", "source_name": "markets.businessinsider.com", "published_at": "2026-06-15T18:40:26", "published_display": "15 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "Immatics (IMTX) reported a Q1 loss of $0.50 per share, missing the Zacks Consensus Estimate of a $0.42 loss, and also fell short on revenue expectations with $8.91 million against an estimate that was 38.95% higher. Despite the disappointing quarter, the company's stock has outpe", "url": "https://www.easternprogress.com/immatics-imtx-reports-q1-loss-lags-revenue-estimates/article_de5209ba-ed1b-5e94-8d9c-32c9507fb356.html", "source_name": "Eastern Progress", "published_at": "2026-06-14T19:09:03", "published_display": "14 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Immatics (IMTX) Advancing Its PRAME Franchise With New ASCO 2026 Data", "summary": "Immatics (IMTX) presented new data at the 2026 ASCO meeting, showcasing deep, durable responses and manageable safety for its PRAME-targeted cell therapies and bispecifics in various solid tumors. The company is building an integrated PRAME franchise, with one asset already in a ", "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-immatics-imtx-advancing-its-prame-franchise-with-new-asco-2026-data-2026-06-14", "source_name": "Sahm", "published_at": "2026-06-13T20:10:12", "published_display": "13 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMTX - Immatics N.V Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news headlines for Immatics N.V. (IMTX). It details the company's stock price, market cap, income, sales, and various financial ratios, along with a list of recent events an", "url": "https://finviz.com/stock?t=IMTX", "source_name": "Finviz", "published_at": "2026-06-11T17:10:23", "published_display": "11 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (IMTX) That Institutions Follow", "summary": "This article analyzes Immatics N.v. (IMTX) through AI models, revealing weak near and mid-term sentiment, potentially challenging a long-term positive outlook. It provides specific institutional trading strategies including position, momentum breakout, and risk hedging, along wit", "url": "https://news.stocktradersdaily.com/news_release/1/The_Technical_Signals_Behind_IMTX_That_Institutions_Follow_061126020002_1781157602.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-11T02:00:00", "published_display": "11 Jun 2026 02:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immatics-presents-clinical-activity-response-120000450.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immatics-presents-data-ima401-magea4-130000251.html", "source_name": "GlobeNewswire", "published_at": "2026-05-31T13:00:00+00:00", "published_display": "31 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics starts dual-target lung cancer trial designed to broaden patient reach", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNMFFBcVJCUXhGdWliTzVSSm1nVV9UakE3UGZPckdteHNULUdiVEkzbkJOUHlSNmJUN3MxOS1FbnNRVmZJeTdoNDI2THBhT3Q5VE0xSHlvY0JWWTFLT0VoZDBRN3hGQW5HTUFwcjd4NEZnUGpEdnNPdlJZekNzTGlub01KSktaR0lPRjFtX0lubHk0Y0tyd3BPRk1VeEdtdjR3Yk1oSV9VOWQzZzNJUVVYcGJ2TkhHRUt2cjRzeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Immatics N.v. (IMTX) Risk Zones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPUlVLajdaR0VVcksyajVjSm9DTHVlb3pFWFRwUk5lUVlJVHdmMkQ1Q2ZoaDFtZ3RId2Q0UG5jWlRTbS1ydHNNc3hLYkg5M0F2TmZES0FJSnhzNlNnUFpXRF93UzZFS3NpSXY5YzZTNm9BZnhqV2Nma0F2eWVZeFJtLWNjNUhRbnN4Z0xrYkNCU09KVkVpZ29LTGMwaFZsVDZsRzZTWHpnQWkwdVZVaDB1cFV1bGJuNjZ5dnN2VE9FQi1malV0cjlsbGNJRQ?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/analysts-updating-immatics-n-v-105938490.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T10:59:38+00:00", "published_display": "15 May 2026 10:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (NASDAQ:IMTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immatics Q1 Loss Widens, Revenue Falls", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immatics-q1-loss-widens-revenue-114051839.html", "source_name": "MT Newswires", "published_at": "2026-05-12T11:40:51+00:00", "published_display": "12 May 2026 11:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immatics-q1-earnings-snapshot-111728776.html", "source_name": "Associated Press", "published_at": "2026-05-12T11:17:28+00:00", "published_display": "12 May 2026 11:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Announces First Quarter 2026 Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxORTY3NV8wcTBwSWFsWFBwY2tta1l5NXdJVTlQZ1RYRW1xQURYQ2daNFFOeEM0MGp5NVlvbzl5WURBOVowTV83YUFsQWdyb1ZxbnppOFVFeGlZc3ZFSjMzQjVDYUFJQ21oTFpSMVc2MzNPa0tkOGxva3hULVMyUzJlYXNTWVJpLVUxNlN0aVNPUWFVbTN6eDZpa1JRZ3RtNXhTWEpzZTd2VHVYZEhFZlBjbmxoZlRfM1hLZk1YTURwNFVwRzlNX1A0SzY1ZV9tOWd1YTMyYkVqU3lRalhndnJCQw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPYUdlQ0Q3X00wNjRNYl9Cb3Z3XzBHc3hYeWt0ZDZGYWNLS1A3WTdRbDZ6ZlBfSkRScnhXbmhHR1B0aTdURGlrQW94ZWtLTFJ4Rjg2SHJqVll6WEdvVzBfSlpad0N4Qy04SzVaU05vekVTT1JETjJUUVpwWXZoa3FDV3hUa0sxYTlZWFBLalhQUTB0ZnBzemNSWXZISVgyYkE?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9YOU5EcGdNUjRYLTdla1Q3UW02ZUtPeVhMdXZjRldDRHQ4cC1sUmpXXzJpTW5NUlc2cDI4OUZfVEotbl85QUtKdVE1ak9pa1g5RVEwXzB5UG51bnR3dWEybk9uNFFhSjJ5UVgzbWxLQ1FHc3B0dV9RM3NB?oc=5", "source_name": "Market source", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdTRIb3NrS3V5ek9paWoza29OUWE2ei15UWdIR05TeF9zd29DSVRmRHFPdHRYRVc3RnVIOVNUaHQ1aWZsQlF5NHByLUx3NlRKQkQ5VENTdmtLQWlTM3pEQTVOTm5oTmR2WEp5d2lJSlVvZWRaeDFfb295QmN0Ukxvd2NuY0lEWHpJREYwajVYeGQ2MHY5QS1RWmxINW8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: PRAME Leader's Transition To Commercial Reality", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNQlFNdUNVdEhrZ3hUZGd4b0F0VG15SG02RU5mcjBzNjZRUmotYTh5cG1ySTl3YTRFWUk4dG82QVdrTk55X2xSS1RhMHJ1T25TZDdSb05jMDNqRnlRVFNSejZpd01LMmpfQWdHTTNGNTltcFYtcHZpYUF0SDlqX3U1bnhOU0dTZWQ2RURRY3lqb3ZmZFVXUUZ6SjFCT3lwdUVLT0ZoXw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQT3RKZngxcXNpRnhnYkNjWkM4cWc2VHoyYVZBMGRaRHlSa0ZWQklPTHB1U252djhOWEd3Yk03S2tsWWlMM3dRMDRNR1lHczRkVkxpVXIxZndiTkt0LWhKTTJWY0d0THh2cFdhMVgzLUZ5QjhoVm1LRFJDb1NOVHgtdERYcDRLeUVyQl83blhRSThJWkZVLXJzS2RTS2g1bzZuT3dHcXpzQkpfdHZBeTBUeGliMlVpbi1YZjJZdE9odERUbmZXUWtj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V (IMTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hdC11U05mOVJ2TXZfQXFXb1RFWC1DQXRjZDVzOUtHSEdLTEFaV1RQRmhtYmVkSnlobEhUNzNIMm40bXdKVnpFWGZPanR5OFRpYmRn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:22:38+00:00", "published_display": "25 Apr 2025 01:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMTX Stock Price and Chart \u2014 NASDAQ:IMTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE55YmZLU21BVVEtVkRUck82WmhIVGFzak1CelJKN2FQV0F5QjE5WHVGRXBrSDFNUUVNa1U1dDRrdlBWaU93dGFNTjN3YllXUWxTR01yMmE0eGRUeGFV?oc=5", "source_name": "TradingView", "published_at": "2023-09-05T07:00:00+00:00", "published_display": "05 Sep 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBrb1NYdUg5b25JOVhjYU5aaGdqWXBuRkRqVjR2M19hd3hoakZHQlRfNnZBdXBmQ0xtck1ZRDNGRTBPSF80X2ppaWg4OWdxMDRrbmhnVGlfLVZ6dw?oc=5", "source_name": "MarketBeat", "published_at": "2020-07-24T15:55:07+00:00", "published_display": "24 Jul 2020 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "(IMTX) and the Role of Price-Sensitive Allocations", "summary": "Immatics N.v. (NASDAQ: IMTX) is showing weak near-term sentiment but strong mid and long-term outlooks, with breakdown currently underway. AI models provide distinct trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe sig", "url": "https://news.stocktradersdaily.com/news_release/1/IMTX_and_the_Role_of_Price-Sensitive_Allocations_071426052802_1784021282.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T05:28:00", "published_display": "14 Jul 2026 05:28", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics stock holds attention. The focus shifts to its pipeline.", "summary": "Immatics N.V. (IMTX) is a cancer immunotherapy company with a pipeline focused on T-cell receptor (TCR) based therapies and cell therapy programs, listed on Nasdaq. The company's value is closely tied to its clinical pipeline performance, including trial milestones, safety signal", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immatics-stock-holds-attention-the-focus-shifts-to-its-pipeline/69716286", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:21:00", "published_display": "07 Jul 2026 17:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the IMTX Inflection", "summary": "This article analyzes Immatics N.v. (NASDAQ: IMTX), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 59.0:1 risk-reward setup targeting an 18.3% gain against 0.3% risk. The piece provides institutional trading strategies for", "url": "https://news.stocktradersdaily.com/news_release/1/Responsive_Playbooks_and_the_IMTX_Inflection_070326042002_1783066802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-04T03:10:06", "published_display": "04 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. Actuals & Estimates (NASDAQ:IMTX)", "summary": "This article provides detailed financial actuals and analyst estimates for Immatics N.V. (IMTX), including stock price performance, growth trends, future forecasts, and historical highs and lows. It covers income statement, balance sheet, cash flow, and valuation metrics, along w", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-29T13:14:47", "published_display": "29 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immatics N.V. \u2013 NASDAQ:IMTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPNXB4bk13R0ttODNCY29YRWh2SGtjSUdmcml1SlRfb1ZfOHRoT2hQRHM5cU12c293dm1WOFpqWTM3em9CZ1prMThCRHlzX3FkdlZ3S1hLUHZJOFhJQnZUTzhQVzBhc0FwZUl3djBjVEt5bmpxYnRQQUZjYndKdTdWenI3bGwtU3hlRGVycmJWTVE0TFJObUNDTkFTV3I?oc=5", "source_name": "TradingView", "published_at": "2026-06-28T20:54:51+00:00", "published_display": "28 Jun 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immatics N.V. \u2013 NASDAQ:IMTX", "summary": "This article provides a brief financial overview of Immatics N.V., focusing on its forward price-to-sales ratio. It indicates the stock's performance on the Nasdaq Stock Market under the ticker IMTX and states that the market is currently closed with no trades. The content primar", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:40:32", "published_display": "28 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Immatics N.V. \u2013 MUN:4A3", "summary": "This article focuses on the enterprise value to EBIT forward for Immatics N.V., traded on the Munich Stock Exchange under the ticker 4A3. It appears to be a financial data presentation and analysis page from TradingView, providing an overview of the company's financial metrics. T", "url": "https://www.tradingview.com/symbols/MUN-4A3/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:40", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immatics N.V. \u2013 NASDAQ:IMTX", "summary": "The article provides a financial overview of Immatics N.V. (NASDAQ: IMTX), focusing on its price-to-earnings forward metric. It highlights that the market was closed with no trades recorded at the time of the data. The content primarily serves as a placeholder or financial data p", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:23", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Immatics N.V. (IMTX) stock, including analyst ratings, historical performance, and financial data. It covers frequently asked questions regarding the stock's current price, volatility, market capitalization, earnings,", "url": "https://www.tradingview.com/symbols/NASDAQ-IMTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T07:11:10", "published_display": "27 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. Actuals & Estimates (FWB:4A3)", "summary": "This article provides key financial actuals and estimates for Immatics N.V. (FWB:4A3), including analyst price targets, historical stock performance, and upcoming earnings dates. It also details the company's past quarterly earnings, revenue, net income, EBITDA, and employee coun", "url": "https://www.tradingview.com/symbols/FWB-4A3/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:53", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director Adam Leo Stone receives 48,000 stock options award", "summary": "Immatics N.V. (IMTX) director Adam Leo Stone was granted 48,000 stock options, with an exercise price of $9.09 per share and an expiration date of June 15, 2036. These options will vest 100% on June 16, 2026, marking them as a compensation-related award rather than an open-market", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-578f11fe8580.html", "source_name": "Stock Titan", "published_at": "2026-06-22T00:40:32", "published_display": "22 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) awards director Alise Reicin 48,000 stock options", "summary": "Immatics N.V. (IMTX) director Alise Reicin was granted 48,000 stock options as compensation. These options allow her to purchase Immatics ordinary shares at an exercise price of $9.09 per share, expire on June 15, 2036, and will vest 100% on June 16, 2026. This transaction was re", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-1a4c67d05561.html", "source_name": "Stock Titan", "published_at": "2026-06-22T00:40:32", "published_display": "22 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Shareholders Approve All Proposals at June 18, 2026 AGM", "summary": "Immatics N.V. held its Annual General Meeting on June 18, 2026, where shareholders approved all resolutions, including the adoption of annual accounts, re-election of directors, extension of share repurchase authority, and approval of a 2026 stock option plan. Despite strong shar", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMTX/pressreleases/2561647/immatics-shareholders-approve-all-proposals-at-june-18-2026-agm/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T09:40:29", "published_display": "20 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director receives 48,000 stock options vesting in 2026", "summary": "Immatics N.V. (IMTX) director Carter Paul Rutherford was granted 48,000 stock options with an exercise price of $9.09 per share, set to expire on June 15, 2036. These options will vest entirely on June 16, 2026, which is the first anniversary of the grant date. This award is a fo", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-ec0814e4dbbf.html", "source_name": "Stock Titan", "published_at": "2026-06-19T23:39:18", "published_display": "19 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Immatics NV (IMTXW), focusing on support, resistance, and various indicators including MACD, RSI, KDJ, and moving averages. The analysis suggests a \"Sell\" signal based on both technical indicators and moving averages due to low volati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/technical", "source_name": "TradingKey", "published_at": "2026-06-19T22:41:11", "published_display": "19 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) director awarded 48,000 stock options at $9.09", "summary": "Immatics N.V. director Peter Alan Chambre was granted 48,000 stock options as part of his compensation, allowing him to purchase ordinary shares at an exercise price of $9.09 each. These options will vest 100% on June 16, 2026, and are set to expire on June 15, 2036. This transac", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-c4af1e59591b.html", "source_name": "Stock Titan", "published_at": "2026-06-19T09:10:41", "published_display": "19 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) grants director options on 48,000 ordinary shares", "summary": "Immatics N.V. (IMTX) director Eliot Forster has been granted stock options for 48,000 ordinary shares. These options have an exercise price of $9.09 per share and a full vesting date of June 16, 2026, one year from the grant date. The options are set to expire on June 15, 2036.", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-80ec640acc2d.html", "source_name": "Stock Titan", "published_at": "2026-06-19T08:41:11", "published_display": "19 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director receives grant of 48,000 stock options at $9.09", "summary": "Immatics N.V. director Michael G. Atieh was granted 48,000 stock options with an exercise price of $9.09 per share. These options will vest 100% on June 16, 2026, which is the first anniversary of the grant date, and are set to expire on June 15, 2036. This transaction is classif", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-25c881ea3108.html", "source_name": "Stock Titan", "published_at": "2026-06-19T08:41:11", "published_display": "19 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) director Mathias Hothum awarded 48,000 options at $9.09 strike", "summary": "Immatics N.V. (IMTX) Director Mathias Hothum was granted 48,000 stock options at an exercise price of $9.09 per share. These compensation-related options vest 100% on June 16, 2026, and will expire on June 15, 2036. Following this transaction, Hothum holds 48,000 derivative secur", "url": "https://www.stocktitan.net/sec-filings/IMTX/form-4-immatics-n-v-insider-trading-activity-1d2ca4ee7272.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:27", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) 2026 AGM sees all voting items approved and strong turnout", "summary": "Immatics N.V. held its Annual General Meeting of Shareholders on June 18, 2026, where all agenda voting items were approved by the required majorities. The meeting had a strong turnout, with approximately 64.07% of the company's issued share capital represented. The minutes of th", "url": "https://www.stocktitan.net/sec-filings/IMTX/6-k-immatics-n-v-current-report-foreign-issuer-ae7c96666072.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:27", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Immatics NV (IMTXW), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it states that relevant data for these valuation metrics have not yet been disclosed by the company. The article serves primarily as a framewo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:12", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) Stock Looks Expensive After PRAME Platform Update And Cash Runway To 2028", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immatics NV's (IMTX) dividend and stock split history, noting that no dividends have been distributed in the past five years and no stock split data is available. It presents current stock performance data, including market capitalization and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:45", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article from TradingKey provides a financial health analysis for Immatics NV (IMTXW), focusing on profitability and its balance sheet. However, the report indicates that relevant financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholde", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:45", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article concerns the revenue breakdown for Immatics NV (IMTXW), detailing its business segments, regional revenue, and profit contribution. However, the critical financial data required for this breakdown has not yet been disclosed by the company, rendering the specific break", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtxw/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T14:41:33", "published_display": "17 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Immatics NV (IMTX) has an earnings forecast score of 8.83, ranking 50th in the biotechnology industry. Analysts overwhelmingly recommend a \"Buy\" for IMTX, with a target price of $17.50, suggesting a potential upside of over 100%. The company expects significant revenue in the upc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imtx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T13:41:33", "published_display": "17 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNenRCSWJQTEw3cDB3ZUtBb3RLS3Nmb3Z0SEhmbTkzNHdhV1BYVWliUnhZWi1QNElhMkVBcU5xX25FUUZ6anR2TmRPdkpWN2lILWdHaHFtLUtuUHZGZGxRSFFUaDM4UHdFU09pLWJVRTJoaUpDeUpjNnFvb3o1bTdKRmlqYVVSSHZhY1ljdU9TSGNkcjdWaF9kOE9nUjNBOS16Yko4SnZpbw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting", "summary": "Immatics announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma, presented at the 2026 ASCO Annual Meeting. The one-time infusion therapy demonstrated significant anti-tumor activity in difficult-to-treat gynecologic ", "url": "https://markets.businessinsider.com/news/stocks/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting-1036209654", "source_name": "markets.businessinsider.com", "published_at": "2026-06-15T18:40:26", "published_display": "15 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "Immatics (IMTX) reported a Q1 loss of $0.50 per share, missing the Zacks Consensus Estimate of a $0.42 loss, and also fell short on revenue expectations with $8.91 million against an estimate that was 38.95% higher. Despite the disappointing quarter, the company's stock has outpe", "url": "https://www.easternprogress.com/immatics-imtx-reports-q1-loss-lags-revenue-estimates/article_de5209ba-ed1b-5e94-8d9c-32c9507fb356.html", "source_name": "Eastern Progress", "published_at": "2026-06-14T19:09:03", "published_display": "14 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Immatics (IMTX) Advancing Its PRAME Franchise With New ASCO 2026 Data", "summary": "Immatics (IMTX) presented new data at the 2026 ASCO meeting, showcasing deep, durable responses and manageable safety for its PRAME-targeted cell therapies and bispecifics in various solid tumors. The company is building an integrated PRAME franchise, with one asset already in a ", "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-immatics-imtx-advancing-its-prame-franchise-with-new-asco-2026-data-2026-06-14", "source_name": "Sahm", "published_at": "2026-06-13T20:10:12", "published_display": "13 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMTX - Immatics N.V Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, analyst ratings, and recent news headlines for Immatics N.V. (IMTX). It details the company's stock price, market cap, income, sales, and various financial ratios, along with a list of recent events an", "url": "https://finviz.com/stock?t=IMTX", "source_name": "Finviz", "published_at": "2026-06-11T17:10:23", "published_display": "11 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (IMTX) That Institutions Follow", "summary": "This article analyzes Immatics N.v. (IMTX) through AI models, revealing weak near and mid-term sentiment, potentially challenging a long-term positive outlook. It provides specific institutional trading strategies including position, momentum breakout, and risk hedging, along wit", "url": "https://news.stocktradersdaily.com/news_release/1/The_Technical_Signals_Behind_IMTX_That_Institutions_Follow_061126020002_1781157602.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-11T02:00:00", "published_display": "11 Jun 2026 02:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immatics-presents-clinical-activity-response-120000450.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immatics-presents-data-ima401-magea4-130000251.html", "source_name": "GlobeNewswire", "published_at": "2026-05-31T13:00:00+00:00", "published_display": "31 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics starts dual-target lung cancer trial designed to broaden patient reach", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNMFFBcVJCUXhGdWliTzVSSm1nVV9UakE3UGZPckdteHNULUdiVEkzbkJOUHlSNmJUN3MxOS1FbnNRVmZJeTdoNDI2THBhT3Q5VE0xSHlvY0JWWTFLT0VoZDBRN3hGQW5HTUFwcjd4NEZnUGpEdnNPdlJZekNzTGlub01KSktaR0lPRjFtX0lubHk0Y0tyd3BPRk1VeEdtdjR3Yk1oSV9VOWQzZzNJUVVYcGJ2TkhHRUt2cjRzeQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Immatics N.v. (IMTX) Risk Zones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPUlVLajdaR0VVcksyajVjSm9DTHVlb3pFWFRwUk5lUVlJVHdmMkQ1Q2ZoaDFtZ3RId2Q0UG5jWlRTbS1ydHNNc3hLYkg5M0F2TmZES0FJSnhzNlNnUFpXRF93UzZFS3NpSXY5YzZTNm9BZnhqV2Nma0F2eWVZeFJtLWNjNUhRbnN4Z0xrYkNCU09KVkVpZ29LTGMwaFZsVDZsRzZTWHpnQWkwdVZVaDB1cFV1bGJuNjZ5dnN2VE9FQi1malV0cjlsbGNJRQ?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/analysts-updating-immatics-n-v-105938490.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T10:59:38+00:00", "published_display": "15 May 2026 10:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (NASDAQ:IMTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Q1 Loss Widens, Revenue Falls", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immatics-q1-loss-widens-revenue-114051839.html", "source_name": "MT Newswires", "published_at": "2026-05-12T11:40:51+00:00", "published_display": "12 May 2026 11:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immatics-q1-earnings-snapshot-111728776.html", "source_name": "Associated Press", "published_at": "2026-05-12T11:17:28+00:00", "published_display": "12 May 2026 11:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics Announces First Quarter 2026 Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxORTY3NV8wcTBwSWFsWFBwY2tta1l5NXdJVTlQZ1RYRW1xQURYQ2daNFFOeEM0MGp5NVlvbzl5WURBOVowTV83YUFsQWdyb1ZxbnppOFVFeGlZc3ZFSjMzQjVDYUFJQ21oTFpSMVc2MzNPa0tkOGxva3hULVMyUzJlYXNTWVJpLVUxNlN0aVNPUWFVbTN6eDZpa1JRZ3RtNXhTWEpzZTd2VHVYZEhFZlBjbmxoZlRfM1hLZk1YTURwNFVwRzlNX1A0SzY1ZV9tOWd1YTMyYkVqU3lRalhndnJCQw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPYUdlQ0Q3X00wNjRNYl9Cb3Z3XzBHc3hYeWt0ZDZGYWNLS1A3WTdRbDZ6ZlBfSkRScnhXbmhHR1B0aTdURGlrQW94ZWtLTFJ4Rjg2SHJqVll6WEdvVzBfSlpad0N4Qy04SzVaU05vekVTT1JETjJUUVpwWXZoa3FDV3hUa0sxYTlZWFBLalhQUTB0ZnBzemNSWXZISVgyYkE?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE9YOU5EcGdNUjRYLTdla1Q3UW02ZUtPeVhMdXZjRldDRHQ4cC1sUmpXXzJpTW5NUlc2cDI4OUZfVEotbl85QUtKdVE1ak9pa1g5RVEwXzB5UG51bnR3dWEybk9uNFFhSjJ5UVgzbWxLQ1FHc3B0dV9RM3NB?oc=5", "source_name": "Market source", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdTRIb3NrS3V5ek9paWoza29OUWE2ei15UWdIR05TeF9zd29DSVRmRHFPdHRYRVc3RnVIOVNUaHQ1aWZsQlF5NHByLUx3NlRKQkQ5VENTdmtLQWlTM3pEQTVOTm5oTmR2WEp5d2lJSlVvZWRaeDFfb295QmN0Ukxvd2NuY0lEWHpJREYwajVYeGQ2MHY5QS1RWmxINW8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics: PRAME Leader's Transition To Commercial Reality", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNQlFNdUNVdEhrZ3hUZGd4b0F0VG15SG02RU5mcjBzNjZRUmotYTh5cG1ySTl3YTRFWUk4dG82QVdrTk55X2xSS1RhMHJ1T25TZDdSb05jMDNqRnlRVFNSejZpd01LMmpfQWdHTTNGNTltcFYtcHZpYUF0SDlqX3U1bnhOU0dTZWQ2RURRY3lqb3ZmZFVXUUZ6SjFCT3lwdUVLT0ZoXw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQT3RKZngxcXNpRnhnYkNjWkM4cWc2VHoyYVZBMGRaRHlSa0ZWQklPTHB1U252djhOWEd3Yk03S2tsWWlMM3dRMDRNR1lHczRkVkxpVXIxZndiTkt0LWhKTTJWY0d0THh2cFdhMVgzLUZ5QjhoVm1LRFJDb1NOVHgtdERYcDRLeUVyQl83blhRSThJWkZVLXJzS2RTS2g1bzZuT3dHcXpzQkpfdHZBeTBUeGliMlVpbi1YZjJZdE9odERUbmZXUWtj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics N.V (IMTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hdC11U05mOVJ2TXZfQXFXb1RFWC1DQXRjZDVzOUtHSEdLTEFaV1RQRmhtYmVkSnlobEhUNzNIMm40bXdKVnpFWGZPanR5OFRpYmRn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:22:38+00:00", "published_display": "25 Apr 2025 01:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMTX Stock Price and Chart \u2014 NASDAQ:IMTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE55YmZLU21BVVEtVkRUck82WmhIVGFzak1CelJKN2FQV0F5QjE5WHVGRXBrSDFNUUVNa1U1dDRrdlBWaU93dGFNTjN3YllXUWxTR01yMmE0eGRUeGFV?oc=5", "source_name": "TradingView", "published_at": "2023-09-05T07:00:00+00:00", "published_display": "05 Sep 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immatics (IMTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBrb1NYdUg5b25JOVhjYU5aaGdqWXBuRkRqVjR2M19hd3hoakZHQlRfNnZBdXBmQ0xtck1ZRDNGRTBPSF80X2ppaWg4OWdxMDRrbmhnVGlfLVZ6dw?oc=5", "source_name": "MarketBeat", "published_at": "2020-07-24T15:55:07+00:00", "published_display": "24 Jul 2020 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 57, "sentiment_summary": {"positive": 9, "negative": 7, "neutral": 41, "score": 52, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.55, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 9.68, "latest_week": "2026-07-10", "one_week_move": -2.7, "four_week_move": 3.2, "twelve_week_move": -13.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.897447, "market_dynamics_buy_signal": false, "relative_strength": -10.265199, "fair_value_gap": 4.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.004, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.7% over one week, +3.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 9}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 6}, {"label": "Stock Traders Daily", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 4}, {"label": "Capital return", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.7% over one week, +3.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "(IMTX) and the Role of Price-Sensitive Allocations"}], "updated_at": "2026-07-16T15:24:18.416493+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}